Fig. 7From: EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanismsAssociations between EXTL3 expression and A AFP464; B AP-26113; C Dexrazoxane; D LDK-378; E palbociclib; F rapamycin; in the CellMiner databaseBack to article page